Loading
FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.90, affected pathway 0.98, animal model 0.53). In OnCo, 1 product record names it (Burosumab).
In plain words · FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.
FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels.
No product in this corpus aims at FGF23 yet. Because it sits on the outside of the cell, it can be reached from the bloodstream: antibodies flag the cell, ADCs deliver a toxin, radioligands deliver radiation, and CAR-T or bispecifics bring a T cell.
Tumour-associated overexpression: 1 antibody (Burosumab) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA FGF23: RNA tissue enhanced (heart muscle 5 nTPM, liver 5 nTPM); blood lineage lineage enriched (granulocytes 9 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 2 specific cancer types at or above 0.5 (tumoral calcinosis, hyperphosphatemic, familial, 2, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome). (Rule 5 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas FGF23 tissue; Human Protein Atlas FGF23 pathology; Open Targets ENSG00000118972 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Yamashita et al, Biochem. Biophys. Res. Commun, 2000, "Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain". Source.
Sources: HGNC HGNC:3680 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9GZV9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000118972 (association with cancer (MONDO_0004992) 0.63; (GraphQL API, CC0))
Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralisation. Location: Secreted (UniProt). Locus 12p13.32 (HGNC).
RNA: tissue enhanced (heart muscle 5 nTPM, liver 5 nTPM), detected in some normal tissues. Blood: lineage enriched (granulocytes 9 nTPM).
No normal tissue stained high.
RNA group enriched: Ovary Serous Cystadenocarcinoma 21 pTPM, Stomach Adenocarcinoma 53 pTPM.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FGF23" OR ABSTRACT:"FGF23" OR TITLE:"fibroblast growth factor 23" OR ABSTRACT:"fibroblast growth factor 23" OR TITLE:"Fibroblast growth factor 23" OR ABSTRACT:"Fibroblast growth factor 23") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FGF23, not a curated reading list.